These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 16151910)

  • 21. Fabry Disease Therapy: State-of-the-Art and Current Challenges.
    Azevedo O; Gago MF; Miltenberger-Miltenyi G; Sousa N; Cunha D
    Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33379210
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of enzyme replacement therapy on clinical outcomes in paediatric patients with Fabry disease - A systematic literature review by a European panel of experts.
    Spada M; Baron R; Elliott PM; Falissard B; Hilz MJ; Monserrat L; Tøndel C; Tylki-Szymańska A; Wanner C; Germain DP
    Mol Genet Metab; 2019 Mar; 126(3):212-223. PubMed ID: 29785937
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hearing loss in Fabry disease: the effect of agalsidase alfa replacement therapy.
    Hajioff D; Enever Y; Quiney R; Zuckerman J; Mackermot K; Mehta A
    J Inherit Metab Dis; 2003; 26(8):787-94. PubMed ID: 14739683
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Home infusion program for Fabry disease: experience with agalsidase alfa in Argentina.
    Kisinovsky I; Cáceres G; Coronel C; Reisin R
    Medicina (B Aires); 2013; 73(1):31-4. PubMed ID: 23335703
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of agalsidase alfa replacement therapy on Fabry disease-related hypertrophic cardiomyopathy: a 12- to 36-month, retrospective, blinded echocardiographic pooled analysis.
    Kampmann C; Linhart A; Devereux RB; Schiffmann R
    Clin Ther; 2009 Sep; 31(9):1966-76. PubMed ID: 19843486
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Control of proteinuria with increased doses of agalsidase alfa in a patient with Fabry disease with atypical genotype-phenotype expression.
    Paliouras C; Aperis G; Lamprianou F; Ntetskas G; Roufas K; Alivanis P
    Nefrologia; 2015; 35(6):578-81. PubMed ID: 26384850
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naïve Fabry disease patients.
    Tsuboi K; Yamamoto H
    BMC Pharmacol Toxicol; 2017 Jun; 18(1):43. PubMed ID: 28592315
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fabry disease in children: agalsidase-beta enzyme replacement therapy.
    Borgwardt L; Feldt-Rasmussen U; Rasmussen AK; Ballegaard M; Meldgaard Lund A
    Clin Genet; 2013 May; 83(5):432-8. PubMed ID: 22880956
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Agalsidase therapy in patients with Fabry disease on renal replacement therapy: a nationwide study in Italy.
    Mignani R; Feriozzi S; Pisani A; Cioni A; Comotti C; Cossu M; Foschi A; Giudicissi A; Gotti E; Lozupone VA; Marchini F; Martinelli F; Bianco F; Panichi V; Procaccini DA; Ragazzoni E; Serra A; Soliani F; Spinelli L; Torti G; Veroux M; Cianciaruso B; Cagnoli L
    Nephrol Dial Transplant; 2008 May; 23(5):1628-35. PubMed ID: 18057066
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Agalsidase alfa--a preparation for enzyme replacement therapy in Anderson-Fabry disease.
    Beck M
    Expert Opin Investig Drugs; 2002 Jun; 11(6):851-8. PubMed ID: 12036428
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enzyme replacement therapy in Fabry disease: comparison of agalsidase alfa and agalsidase beta.
    Mehta A; Beck M; Kampmann C; Frustaci A; Germain DP; Pastores GM; Sunder-Plassmann G
    Mol Genet Metab; 2008; 95(1-2):114-5. PubMed ID: 18701330
    [No Abstract]   [Full Text] [Related]  

  • 32. Kidney function and 24-hour proteinuria in patients with Fabry disease during 36 months of agalsidase alfa enzyme replacement therapy: a Brazilian experience.
    Thofehrn S; Netto C; Cecchin C; Burin M; Matte U; Brustolin S; Nunes AC; Coelho J; Tsao M; Jardim L; Giugliani R; Barros EJ
    Ren Fail; 2009; 31(9):773-8. PubMed ID: 19925283
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preservation of renal function in a patient with Fabry nephropathy on enzyme replacement therapy.
    Torra R; Algaba F; Ars E; Santin S; Fernández-Llama P; Ballarin J
    Clin Nephrol; 2008 Jun; 69(6):445-9. PubMed ID: 18538121
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Agalsidase alfa and kidney dysfunction in Fabry disease.
    West M; Nicholls K; Mehta A; Clarke JT; Steiner R; Beck M; Barshop BA; Rhead W; Mensah R; Ries M; Schiffmann R
    J Am Soc Nephrol; 2009 May; 20(5):1132-9. PubMed ID: 19357250
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa.
    Hughes DA; Elliott PM; Shah J; Zuckerman J; Coghlan G; Brookes J; Mehta AB
    Heart; 2008 Feb; 94(2):153-8. PubMed ID: 17483124
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relief of gastrointestinal symptoms under enzyme replacement therapy [corrected] in patients with Fabry disease.
    Dehout F; Roland D; Treille de Granseigne S; Guillaume B; Van Maldergem L
    J Inherit Metab Dis; 2004; 27(4):499-505. PubMed ID: 15303007
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of placental tissue in Fabry disease with and without enzyme replacement therapy.
    Bouwman MG; Hollak CE; van den Bergh Weerman MA; Wijburg FA; Linthorst GE
    Placenta; 2010 Apr; 31(4):344-6. PubMed ID: 20189642
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oral Migalastat HCl Leads to Greater Systemic Exposure and Tissue Levels of Active α-Galactosidase A in Fabry Patients when Co-Administered with Infused Agalsidase.
    Warnock DG; Bichet DG; Holida M; Goker-Alpan O; Nicholls K; Thomas M; Eyskens F; Shankar S; Adera M; Sitaraman S; Khanna R; Flanagan JJ; Wustman BA; Barth J; Barlow C; Valenzano KJ; Lockhart DJ; Boudes P; Johnson FK
    PLoS One; 2015; 10(8):e0134341. PubMed ID: 26252393
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Spotlight on agalsidase beta in Fabry disease.
    Keating GM; Simpson D
    BioDrugs; 2007; 21(4):269-71. PubMed ID: 17628124
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease.
    Ries M; Clarke JT; Whybra C; Timmons M; Robinson C; Schlaggar BL; Pastores G; Lien YH; Kampmann C; Brady RO; Beck M; Schiffmann R
    Pediatrics; 2006 Sep; 118(3):924-32. PubMed ID: 16950982
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.